1,962
Views
0
CrossRef citations to date
0
Altmetric
Research Article

A Comprehensive Bioinformatic Analysis of RanBP9 Expression and Its Relation to Prognosis in Human Breast Cancer

, , , , &
Pages 27-42 | Received 14 Nov 2021, Accepted 22 Nov 2021, Published online: 08 Dec 2021

References

  • Sung H , FerlayJ , SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer Cancer J. Clin.71(3), 209–249 (2021).
  • Britt KL , CuzickJ , PhillipsKA. Key steps for effective breast cancer prevention. Nat. Rev. Cancer20(8), 417–436 (2020).
  • Zhang B , LiY , LiLet al. Association study of susceptibility loci with specific breast cancer subtypes in Chinese women. Breast Cancer Res. Treat.146(3), 503–514 (2014).
  • Perou CM , SørlieT , EisenMBet al. Molecular portraits of human breast tumours. Nature406(6797), 747–752 (2000).
  • Goldhirsch A , WoodWC , CoatesASet al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol.22(8), 1736–1747 (2011).
  • Burstein HJ , SomerfieldMR , BartonDLet al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO Guideline Update. J. Clin. Oncol. doi:10.1200/jco.21.01392Jco2101392 (2021) ( Epub ahead of print).
  • Moy B , RumbleRB , ComeSEet al. Chemotherapy and Targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update. J. Clin. Oncol. doi:10.1200/jco.21.01374Jco2101374 (2021) ( Epub ahead of print).
  • Rao MA , ChengH , QuayleANet al. RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor. J. Biol. Chem.277(50), 48020–48027 (2002).
  • Huffman N , PalmieriD , CoppolaV. The CTLH complex in cancer cell plasticity. J. Oncol.2019, 4216750 (2019).
  • Maitland MER , OneaG , ChiassonCAet al. The mammalian CTLH complex is an E3 ubiquitin ligase that targets its subunit muskelin for degradation. Sci. Rep.9(1), 9864 (2019).
  • Salemi LM , MaitlandMER , MctavishCJ , Schild-PoulterC. Cell signalling pathway regulation by RanBPM: molecular insights and disease implications. Open Biol.7(6), (2017).
  • Liu T , RohSE , WooJAet al. Cooperative role of RanBP9 and P73 in mitochondria-mediated apoptosis. Cell Death Dis.4(1), e476 (2013).
  • Palmieri D , TessariA , CoppolaV. Scorpins in the DNA damage response. Int. J. Mol. Sci.19(6), (2018).
  • Zhao Z , ChengS , ZabkiewiczCet al. Reduced expression of RanBPM is associated with poorer survival from lung cancer and increased proliferation and invasion of lung cancer cells in vitro. Anticancer Res.37(8), 4389–4397 (2017).
  • Shao S , SunPH , SatherleyLKet al. Reduced RanBPM expression is associated with distant metastasis in gastric cancer and chemoresistance. Anticancer Res.36(3), 1295–1303 (2016).
  • Qin C , ZhangQ , WuG. RANBP9 suppresses tumor proliferation in colorectal cancer. Oncol. Lett.17(5), 4409–4416 (2019).
  • Wang D , LiZ , MessingEM , WuG. Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J. Biol. Chem.277(39), 36216–36222 (2002).
  • Zou Y , LimS , LeeKet al. Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial cell migration and is negatively regulated by the Met adaptor Ran-binding protein M. J. Biol. Chem.278(49), 49573–49581 (2003).
  • Forbes SA , BeareD , GunasekaranPet al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res.43, D805–811 (2015).
  • Tessari A , ParbhooK , PawlikowskiMet al. RANBP9 affects cancer cells response to genotoxic stress and its over expression is associated with worse response to platinum in NSCLC patients. Oncogene37(50), 6463–6476 (2018).
  • Rhodes DR , Kalyana-SundaramS , MahavisnoVet al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia9(2), 166–180 (2007).
  • Chandrashekar DS , BashelB , BalasubramanyaSaHet al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia19(8), 649–658 (2017).
  • Tang Z , LiC , KangBet al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res.45(W1), W98–w102 (2017).
  • Li T , FanJ , WangBet al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res.77(21), e108–e110 (2017).
  • Vasaikar SV , StraubP , WangJ , ZhangB. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res.46(D1), D956–d963 (2018).
  • Gao J , AksoyBA , DogrusozUet al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal.6(269), pl1 (2013).
  • Franz M , RodriguezH , LopesCet al. GeneMANIA update 2018. Nucleic Acids Res.46(W1), W60–w64 (2018).
  • Fleischer T , TekpliX , MathelierAet al. DNA methylation at enhancers identifies distinct breast cancer lineages. Nat. Commun.8(1), 1379 (2017).
  • Jovanovic J , RønnebergJA , TostJ , KristensenV. The epigenetics of breast cancer. Mol. Oncol.4(3), 242–254 (2010).
  • Tang Z , ZhuM , ZhongQ. Self-eating to remove cilia roadblock. Autophagy10(2), 379–381 (2014).
  • Park HM , KimH , LeeKH , ChoJY. Analysis of opposing histone modifications H3K4me3 and H3K27me3 reveals candidate diagnostic biomarkers for TNBC and gene set prediction combination. BMB Rep.53(5), 266–271 (2020).
  • Tang S , ZhaoY , HeXet al. Identification of NOVA family proteins as novel β-catenin RNA-binding proteins that promote epithelial-mesenchymal transition. RNA Biol.17(6), 881–891 (2020).
  • Kelemen LE , WangX , FredericksenZSet al. Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. Cancer Epidemiol. Biomarkers Prev.18(6), 1864–1868 (2009).
  • Tuttle R , MillerKR , MaioranoJNet al. Novel senescence associated gene, YPEL3, is repressed by estrogen in ER+ mammary tumor cells and required for tamoxifen-induced cellular senescence. Int. J. Cancer130(10), 2291–2299 (2012).
  • Wittmann S , BaliP , DonapatySet al. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res.63(1), 93–99 (2003).
  • Shen G , HeP , MaoYet al. Over expression of uridine-cytidine kinase 2 correlates with breast cancer progression and poor prognosis. J. Breast Cancer20(2), 132–141 (2017).
  • Zati Zehni A , JeschkeU , HesterAet al. EP3 is an independent prognostic marker only for unifocal breast cancer cases. Int. J. Mol. Sci.21(12), (2020).
  • Goh JY , FengM , WangWet al. Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nat. Med.23(11), 1319–1330 (2017).
  • Wei JD , KimJY , KimAKet al. RanBPM protein acts as a negative regulator of BLT2 receptor to attenuate BLT2-mediated cell motility. J. Biol. Chem.288(37), 26753–26763 (2013).
  • Wei JD , JangJH , KimJH. RanBPM inhibits BLT2-mediated IL-8 production and invasiveness in aggressive breast cancer cells. Biochem. Biophys. Res. Commun.483(1), 305–311 (2017).
  • Wu CY , LauBT , KimHSet al. Integrative single-cell analysis of allele-specific copy number alterations and chromatin accessibility in cancer. Nat. Biotechnol.39(10), 1259–1269 (2021).
  • Vogelstein B , PapadopoulosN , VelculescuVEet al. Cancer genome landscapes. Science339(6127), 1546–1558 (2013).
  • Győrffy B , BottaiG , FleischerTet al. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. Int. J. Cancer138(1), 87–97 (2016).
  • Absmaier M , NapieralskiR , SchusterTet al. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. Int. J. Oncol.52(3), 755–767 (2018).
  • Hanahan D , WeinbergRA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
  • Finn RS , AleshinA , SlamonDJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res.18(1), 17 (2016).
  • De Nonneville A , FinettiP , BirnbaumDet al. WEE1 dependency and pejorative prognostic value in triple-negative breast cancer. Adv. Sci. (Weinh).8(17), e2101030 (2021).
  • Freeman-Cook K , HoffmanRL , MillerNet al. Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. Cancer Cell39(10), 1404–1421.e1411 (2021).